HemaClear® Recommended to NICE as Standard of Care in Bloodless Orthopedic Surgery

HemaClear® was recommended as a new and necessary guideline for prevention of Surgical Site Infection (SSI), as part of a clinical study published last week in the Annals of The Royal College of Surgeons of England.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Haifa, Israel (PRWEB) November 23, 2011

HemaClear® today announced that its proprietary disposable tourniquet solution has been recommended to the National Institute for Health and Clinical Excellence (NICE) as a standard of care in bloodless orthopedic limb surgery. HemaClear® was recommended as a new and necessary guideline for prevention of Surgical Site Infection (SSI), as part of a clinical study published last week in the Annals of The Royal College of Surgeons of England.

The study, ”The Effect of Sterile Versus Non –Sterile Tourniquets on Microbiological Colonization in Lower Limb Surgery”, conducted by researchers at St. Peter’s Hospital in Chertsey, UK, is the first to compare the microbiological colonization load of reusable pneumatic tourniquet solutions versus the single use HemaClear® exsanguinating surgical tourniquet, in total knee arthroplasty. Samples of both types of tourniquets were taken at the end of the procedures, sealed, cultured and then incubated.

The results of the study showed that HemaClear® was bacteria free in all cases preformed, not only prior to application, but also at the end of the procedure. 68% of the pneumatic tourniquets, on the contrary, were shown to be contaminated by an array of bacteria.

Half of the bacteria loaded pneumatic tourniquets were contaminated with the bacteria Staphylococcus app. This bacterium is the single most common cause for infection in total knee replacement and arthroscopy, causing alone an infection rate of 1%-3% of knee procedures. Other bacteria present on the pneumatic tourniquet included Bacillus spp, coliform, and Sphingomonas paucimobilis. Bacteria cause surgical site infections which are associated with an acute increase in patient related costs, as well as poor clinical outcome and prolonged patient hospitalization.

The research team concluded the study by stating that “The availability of an alternative (tourniquet solution) should now set the new standard of care and we recommend adopting this as a current NICE guideline for control of SSI”. For more information regarding the study, please refer to http://www.ncbi.nlm.nih.gov/pubmed/22041233.

About HemaClear
Headquartered in Haifa, Israel, HemaClear® is the no buttons, no tubing, no electricity, no smell, no beeps or leaks surgical tourniquet that creates a bloodless field in seconds. HemaClear's simple, innovative and cost-effective technology replaces traditional devices, completely eliminating the need for a tourniquet machine, tourniquet cuff, Esmarch bandage, Webril™ and stockinet. It is the first and only disposable tourniquet with controlled pressure, effective exsanguination, and complete sterility that saves operating room time, reduces risks of infection and enhances surgical performance. Hemaclear is used as a standard of care for bloodless orthopedic surgery in over 25 countries and over 250,000 of Hemaclear’s tourniquets have been applied. Over 15 clinical publications have been published, documenting the different ease of use, clinical and safety advantages of the product.

For more information, visit the HemaClear site at http://www.Hemaclear.com, visit http://www.youtube.com/watch?v=clYxiOGhj5Y or join the Facebook page of the company's mascot, Henry HemaClear, a virtual sales representative and superhero overcoming non-sterile operating procedures worldwide.

Contact:
Grant Castor
U.S. National Sales Manager
Grant(at)hemaclear(dot)com
(267) 549-8797

Omer Inbar
International Sales Manager
Omer(at)hemaclear(dot)com
(972) 54-7827289

###


Contact

  • Grant Castor
    OHK Medical Devices
    (267) 549-8797
    Email